3-羟基-[1,1'-联苯基]-4-羧酸乙酯 | 148066-43-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-羟基-[1,1'-联苯基]-4-羧酸乙酯
• 英文名称: ethyl ester of p-phenylsalicylic acid
• 英文别名: ethyl ester of 2-hydroxy-4-phenylbenzoic acid；2-hydroxy-4-phenylbenzoic acid ethyl ester；ethyl 3-hydroxy-[1,1'-biphenyl]-4-carboxylate；3-hydroxy-biphenyl-4-carboxylic acid ethyl ester；3-Hydroxy-biphenyl-4-carbonsaeure-aethylester；ethyl 2-hydroxy-4-phenylbenzoate
• CAS: 148066-43-7
• 化学式: C₁₅H₁₄O₃
• 分子量: 242.274
• InChiKey: IPQJSJQTJGPTKP-UHFFFAOYSA-N

物化性质

• 熔点：
  44-45 °C
• 沸点：
  190 °C(Press: 0.3 Torr)
• 密度：
  1.167±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-羟基-[1,1'-联苯基]-4-羧酸乙酯 在 喹啉 、 氢氧化钾 、 copper oxide-chromium oxide 作用下， 生成 间羟基联苯
  参考文献：
  名称：

  27.对羟基亚甲基苯乙酮烷基醚的一些观察

  摘要：

  DOI：

  10.1039/jr9390000120
• 作为产物：
  描述：

  (E)-3-(furan-2-yl)-1-phenyl-2-propen-1-one 在 +> 作用下， 生成 3-羟基-[1,1'-联苯基]-4-羧酸乙酯
  参考文献：
  名称：

  呋喃环作为2-cyclohexen-1-one芳构化中的核反应物

  摘要：

  DOI：

  10.1007/bf00531495

文献信息

• EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS
  申请人：Martinez-Perez Jose Antonio

  公开号：US20100094014A1

  公开（公告）日：2010-04-15

  The present invention provides novel compounds of Formula (I) and Formula (I(a)), or the pharmaceutically acceptable salts thereof; methods for treating neurological disorders and neurodegenerative diseases, particularly pain and migraine, comprising administering a compound of Formula (I) or Formula (I(a)); and processes for preparing compounds of Formula (I) or Formula (I(a)).

  本发明提供了公式（I）和公式（I（a））的新化合物，或其药学上可接受的盐；治疗神经系统疾病和神经退行性疾病的方法，特别是治疗疼痛和偏头痛，包括给予公式（I）或公式（I（a））的化合物；以及制备公式（I）或公式（I（a））化合物的过程。
• Excitatory amino acid receptor antagonists
  申请人：Arnold Brian Macklin

  公开号：US20060100237A1

  公开（公告）日：2006-05-11

  The present invention provides novel compounds of Formula (I) and Formula (I(a)), or the pharmaceutically acceptable salts thereof; methods for treating neurological disorders and neurodegenerative diseases, particularly pain and migraine, comprising administering a compound of Formula (I) or Formula (I(a)); and processes for preparing compounds of Formula (I) or Formula (I(a)).

  本发明提供了公式（I）和公式（I（a））的新化合物，或其药学上可接受的盐；用于治疗神经系统疾病和神经退行性疾病，特别是疼痛和偏头痛的方法，包括给予公式（I）或公式（I（a））的化合物；以及制备公式（I）或公式（I（a））化合物的过程。
• Ruthenium(II)-Catalyzed Synthesis of Hydroxylated Arenes with Ester as an Effective Directing Group
  作者：Yiqing Yang、Yun Lin、Yu Rao

  DOI：10.1021/ol301104n

  日期：2012.6.1

  An unprecedented Ru(II) catalyzed ortho-hydroxylation has been developed for the facile synthesis of a variety of multifunctionalized arenes from easily accessible ethyl benzoates with ester as an efficient directing group. Both the TFA/TFAA cosolvent system and oxidants serve as the critical success factors in this transformation. The reaction demonstrates excellent reactivity, good functional group tolerance, and high yields.
• GluK1 antagonists from 6-(carboxy)phenyl decahydroisoquinoline derivatives. SAR and evaluation of a prodrug strategy for oral efficacy in pain models
  作者：Jose A. Martinez-Perez、Smriti Iyengar、Harlan E. Shannon、David Bleakman、Andrew Alt、Brian M. Arnold、Michael G. Bell、Thomas J. Bleisch、Ana M. Castaño、Miriam Del Prado、Esteban Dominguez、Ana M. Escribano、Sandra A. Filla、Ken H. Ho、Kevin J. Hudziak、Carrie K. Jones、Ana Mateo、Brian M. Mathes、Edward L. Mattiuz、Ann Marie L. Ogden、Rosa Maria A. Simmons、Douglas R. Stack、Robert E. Stratford、Mark A. Winter、Zhipei Wu、Paul L. Ornstein

  DOI：10.1016/j.bmcl.2013.09.046

  日期：2013.12

  The synthesis and structure-activity relationship of decahydroisoquinoline derivatives with various benzoic acid substitutions as GluK1 antagonists are described. Potent and selective antagonists were selected for a tailored prodrug approach in order to facilitate the evaluation of the new compounds in pain models after oral administration. Several diester prodrugs allowed for acceptable amino acid exposure and moderate efficacy in vivo. (C) 2013 Elsevier Ltd. All rights reserved.
• Bi-aryl Analogues of Salicylic Acids: Design, Synthesis and SAR Study to Ameliorate Endoplasmic Reticulum Stress
  作者：Ye Eun Kim、Dong Hwan Kim、Ami Choi、Seoul Jang、Kwiwan Jeong、Young-mi Kim、Tae-gyu Nam

  DOI：10.2147/dddt.s319287

  日期：——

  Introduction: Endoplasmic reticulum (ER) stress condition is characterized as the accumulation of misfolded or unfolded proteins in lumen of ER. This condition has been implicated in various diseases and pathologies including β-cell apoptosis, Alzheimer's disease and atherosclerosis. We have reported that hydroxynaphthoic acids (HNA), naphthalene analogues of salicylic acid (SA), reduced ER stress. In this study, we explored structural modification to bi-aryl analogues of SA. Methods: Palladium-catalyzed cross-coupling was applied to synthesize bi-aryl analogues of SA. Anti-ER stress activity was monitored by using our cell-based assay system where ER stress is induced by tunicamycin. To monitor ER stress markers, ER stress was induced physiologically relevant palmitate system. Results: Many analogues decreased ER stress signal induced by tunicamycin. Compounds creating dihedral angle between Ar group and SA moiety generally increased the activity but gave some cytotoxicity to indicate the crucial role of flat conformation of aromatic region. The best compound (16e) showed up to almost 6-fold and 90-fold better activity than 3-HNA and tauro-ursodeoxycholic acid, positive controls, respectively. ER stress markers such as p-PERK and p-JNK were accordingly decreased in Western blotting upon treatment of 16e under palmitate-induced condition. Conclusion: Anti-ER stress activity and toxicity profile of bi-aryl analogues of SA could provide a novel platform for potential therapy for protein misfolding diseases.